MOUNJAERO Trademark

Trademark Overview


On Monday, December 13, 2021, a trademark application was filed for MOUNJAERO with the United States Patent and Trademark Office. The USPTO has given the MOUNJAERO trademark a serial number of 97169562. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 19, 2023. This trademark is owned by Eli Lilly and Company. The MOUNJAERO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
mounjaero

General Information


Serial Number97169562
Word MarkMOUNJAERO
Filing DateMonday, December 13, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 19, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 20, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 16, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Tuesday, June 20, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 19, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, November 15, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 20, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 20, 2022PUBLISHED FOR OPPOSITION
Wednesday, August 31, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, August 12, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 12, 2022ASSIGNED TO EXAMINER
Thursday, December 16, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 16, 2021NEW APPLICATION ENTERED